Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

While investing in biotech stocks can be risky due to clinical trial failures and regulatory hurdles, successful drug approvals can result in massive stock gains. Let’s look at two such growth stocks ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Amyloidosis occurs due to a buildup of amyloid proteins in the body. Along with treatment, complementary therapy can help with symptoms. Some examples include movements, such as yoga, sleep ...

Previously known as primary amyloidosis, systemic amyloid light chain (AL) amyloidosis is the most common form of systemic amyloidosis in developed countries. Although occasionally localized and ...

and nerve damage (polyneuropathy). It is being developed for both inherited and non-inherited forms of TTR amyloidosis, a systemic, progressive and fatal condition. There are estimated to be up to ...

Amvuttra is used in adults to treat polyneuropathy (nerve damage) related to hereditary amyloid transthyretin-mediated (hATTR) amyloidosis. This is a rare genetic (inherited) condition that causes ...